Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
Ain Shams Maternity Hospital, Cairo, Egypt
Auckland Hospital, Auckland, New Zealand
Manukau Surgery Centre, Auckland, New Zealand
North Shore Hospital, Auckland, New Zealand
Hospital for Special Surgery, New York, New York, United States
Hospital of South West Denmark, Esbjerg, Denmark
Hadassah Medical Organization, Jerusalem, Israel
South Australia Ambulance Service, Eastwood, South Australia, Australia
St John Ambulance, Albany, New Zealand
NNSW Medical Retrieval Service, Lismore, New South Wales, Australia
Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Hospital Universitario de San Juan de Alicante, Alicante, Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hospital Universitario de Cruces, Barakaldo,, Vizcaya, Spain
Hospital das Clinicas - University of Sao Paulo, Sao Paulo, Brazil
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.